Evidence map›Paper›PMID 39224593›Full record

ArticleFrontiers in immunology2024

Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.

Raquel Sainz-Amo, Alexander Rodero Romero, Enric Monreal, Juan Luis Chico García, José Ignacio Fernández Velasco, Noelia Villarrubia, Jose Luis Veiga González, Susana Sainz de la Maza, Fernando Rodríguez Jorge, Jaime Masjuan and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Exercise Training and Biomarkers of Neuroaxonal Injury in Multiple Sclerosis: Narrative Review.International journal of environmental research and public health · 2026
    Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Raquel Sainz-Amo *Neurology Department, Hospital Universitario Ramón y Cajal, La Red Española de Esclerosis Multiple, Red de Enfermedades Inflamatorias, Instituto de Salud Carlos III (ISCIII), Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Alexander Rodero Romero *Immunology Department, Hospital Universitario Ramón y Cajal, La Red Española de Esclerosis Multiple, Red de Enfermedades Inflamatorias, Instituto de Salud Carlos III, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Enric Monreal *Neurology Department, Hospital Universitario Ramón y Cajal, La Red Española de Esclerosis Multiple, Red de Enfermedades Inflamatorias, Instituto de Salud Carlos III (ISCIII), Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Juan Luis Chico GarcíaNeurology Department, Hospital Universitario Ramón y Cajal, La Red Española de Esclerosis Multiple, Red de Enfermedades Inflamatorias, Instituto de Salud Carlos III (ISCIII), Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
José Ignacio Fernández VelascoImmunology Department, Hospital Universitario Ramón y Cajal, La Red Española de Esclerosis Multiple, Red de Enfermedades Inflamatorias, Instituto de Salud Carlos III, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Noelia VillarrubiaImmunology Department, Hospital Universitario Ramón y Cajal, La Red Española de Esclerosis Multiple, Red de Enfermedades Inflamatorias, Instituto de Salud Carlos III, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Jose Luis Veiga GonzálezImmunology Department, Hospital Universitario Ramón y Cajal, La Red Española de Esclerosis Multiple, Red de Enfermedades Inflamatorias, Instituto de Salud Carlos III, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Susana Sainz de la MazaNeurology Department, Hospital Universitario Ramón y Cajal, La Red Española de Esclerosis Multiple, Red de Enfermedades Inflamatorias, Instituto de Salud Carlos III (ISCIII), Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Fernando Rodríguez JorgeNeurology Department, Hospital Universitario Ramón y Cajal, La Red Española de Esclerosis Multiple, Red de Enfermedades Inflamatorias, Instituto de Salud Carlos III (ISCIII), Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Jaime MasjuanNeurology Department, Hospital Universitario Ramón y Cajal, La Red Española de Esclerosis Multiple, Red de Enfermedades Inflamatorias, Instituto de Salud Carlos III (ISCIII), Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Lucienne Costa-FrossardNeurology Department, Hospital Universitario Ramón y Cajal, La Red Española de Esclerosis Multiple, Red de Enfermedades Inflamatorias, Instituto de Salud Carlos III (ISCIII), Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Luisa María VillarImmunology Department, Hospital Universitario Ramón y Cajal, La Red Española de Esclerosis Multiple, Red de Enfermedades Inflamatorias, Instituto de Salud Carlos III, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Alemtuzumab is a highly effective pulsed immune reconstitution therapy for multiple sclerosis (MS). Aim: To evaluate serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) in patients with relapsing-remitting MS who have been treated with Alemtuzumab over the course of 2 years. Methods: This prospective study involved MS patients treated with Alemtuzumab at a referral MS center. Both sNfL and sGFAP were analyzed at baseline and then again at 6, 12, and 24 months post-treatment using the single molecule array (SiMoA) technique. We also recruited matched healthy controls (HCs) for comparison. Results: The study included 46 patients (with a median age of 34.2 [Interquartile range (IQR), 28.7-42.3] years, 27 of which were women [58%]) and 76 HCs. No differences in demographic characteristics were observed between patients and HC. The median disease duration was 6.22 (IQR, 1.56-10.13) years. The median annualized relapse rate before treatment was 2 (IQR, 1-3). At baseline, sNfL and sGFAP levels were higher in MS patients (median of 18.8 [IQR, 10.7-52.7] pg/ml and 158.9 [IQR, 126.9-255.5] pg/ml, respectively) when compared to HC (6.11 [IQR, 2.03-8.54] pg/ml and 91.0 [72.6-109] pg/ml, respectively) (p<0.001 for both comparisons). The data indicates that 80% of patients had high (≥10 pg/ml) sNfL values at baseline. We observed a significant decrease in sNfL levels at 6 (65%, p = 0.02), 12 (70.8%, p<0.001), and 24 (78.1%, p<0.001) months. sNfL reached similar levels to HC only after 24 months of Alemtuzumab treatment. During the follow-up period, no changes were identified in the sGFAP values. Conclusion: Alemtuzumab leads to the normalization of sNfL values in MS patients after 2 years of treatment, with no apparent effect on sGFAP values.

Indexed as

AlemtuzumabGlial Fibrillary Acidic ProteinMultiple Sclerosis, Relapsing-RemittingNeurofilament ProteinsAdultBiomarkersFemaleHumansImmunologic FactorsMaleMultiple SclerosisProspective StudiesTreatment OutcomeAlemtuzumabBiomarkersGFAP protein, humanGlial Fibrillary Acidic ProteinImmunologic Factorsneurofilament protein LNeurofilament Proteinsalemtuzumabmultiple sclerosissGFAPSiMoAsNfL

Identifiers

PMID39224593
PMCPMC11366608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.